G
Genmab A/S (GMAB)
NMS – Real vaqt narxi. Valyuta: USD
31.40
+0.55 (1.77%)
Bozor ochiq: Aug 12, 2026, 11:26 AM EDT
31.24
+0.39 (1.28%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
31.40
+0.55 (1.77%)
Bozor ochiq: Aug 12, 2026, 11:26 AM EDT
31.24
+0.39 (1.28%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Genmab A/S, biotexnologiya kompaniyasi, Daniyada saraton va boshqa kasalliklarni davolash uchun antitelarga asoslangan mahsulotlar va mahsulot nomzodlarini ishlab chiqadi. Kompaniya EPKINLY va TEPKINLY ni kattalar bemorlarda qaytalangan yoki refrakter (R/R) diffuz katta B-hujayrali limfoma (DLBCL), katta B-hujayrali limfoma va follikulyar limfoma (FL) uchun; va Tivdak ni kimyoterapiya paytida yoki undan keyin kasallik rivojlangan takroriy/metastatik bachadon bo'yni saratoni bo'lgan kattalar bemorlar uchun sotadi. Shuningdek, u Epcoritamab ni R/R DLBCL va FL, birinchi qator DLBCL va FL, B-hujayrali non-Xochkin limfoma, R/R surunkali limfotsitar leykemiya va Richter sindromi, hamda bolalarda agressiv etuk B-hujayrali neoplazmalar uchun; tisotumab vedotin ni qattiq o'smalar uchun; Acasunlimab ni qattiq o'smalar va kichik hujayrali bo'lmagan o'pka saratoni (NSCLC) uchun; Rinatabart Sesutecan ni platina-rezistent tuxumdon saratoni va qattiq o'smalar uchun; GEN1059, GEN1055 va GEN1057 ni qattiq o'smalar uchun; va GEN1286 ni rivojlangan qattiq o'smalar uchun ishlab chiqmoqda. Bundan tashqari, kompaniya DARZALEX/DARZALEX FASPRO ni ko'p miyeloma (MM) va engil zanjirli amiloidoz uchun; RYBREVANT ni NSCLC uchun; TECVAYLI va TALVEY ni R/R MM uchun; Kesimpta ni takrorlanuvchi ko'p skleroz uchun; va TEPEZZA ni qalqonsimon bez kasalliklari uchun taklif etadi. Shuningdek, u Amivantamab ni takroriy/metastatik bosh va bo'yin saratoni, hamda rivojlangan yoki metastatik kolorektal saraton uchun; Amlenetug ni ko'p tizimli atrofiya uchun; Inclacumab ni sil kasalligi bilan bog'liq vazookklyuziv inqirozlar uchun; va Mim8 ni gemofiliya A uchun ishlab chiqmoqda. Kompaniya AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S va argenx bilan hamkorlik shartnomasiga ega. Genmab A/S 1998 yilda tashkil etilgan va shtab-kvartirasi Kopengagagen, Daniyada joylashgan.
There is no data to display
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-06 | 6-K | gmab-20260630.htm |
| 2026-07-15 | 6-K | gmab_20260715x6k.htm |
| 2026-06-29 | 6-K | gmab_20260629x6k.htm |
| 2026-06-17 | 6-K | gmab_20260617x6k.htm |
| 2026-06-16 | 6-K | gmab_20260616x6k.htm |
| 2026-06-15 | 6-K | gmab_20260615xx6k.htm |
| 2026-06-11 | 6-K | gmab_20260611xx6k.htm |
| 2026-05-29 | 6-K | gmab_29052026x6k.htm |
| 2026-05-13 | 6-K | gmab_20260513x6k.htm |
| 2026-05-12 | 6-K | gmab_20260512x6k.htm |